Tonix Pharmaceuticals Holding (TNXP) Accumulated Depreciation (2017 - 2026)

Tonix Pharmaceuticals Holding has reported Accumulated Depreciation for 10 years, with the latest figure at $7.2 million in Q2 2026.

• On a quarterly basis, Accumulated Depreciation rose 41.85% year-over-year to $7.2 million in Q2 2026; TTM through Jun 2026 was $7.2 million, a 41.85% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 46.99% from the prior year.
• Accumulated Depreciation was $7.2 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $6.6 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $7.2 million in Q2 2026, with the low at $463000.0 in Q1 2022.
• Average Accumulated Depreciation over 5 years is $4.0 million, with a median of $4.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Accumulated Depreciation jumped 513.63% in 2023, then declined 27.53% in 2025.
• Over 5 years, Accumulated Depreciation stood at $1.7 million in 2022, then jumped by 224.38% to $5.4 million in 2023, then retreated by 23.59% to $4.1 million in 2024, then jumped by 46.99% to $6.0 million in 2025, then increased by 19.5% to $7.2 million in 2026.
• The last three Accumulated Depreciation figures came in at $7.2 million (Q2 2026), $6.6 million (Q1 2026), and $6.0 million (Q4 2025), per Business Quant data.